| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 2, Issue 11 561-566, Copyright © 1991 by American Association of Cancer Research
ARTICLES |
S Pizette, M Batoz, H Prats, D Birnbaum and F Coulier
Institut National de la Sante et de la Recherche Medicale, Unite 119, Marseille, France.
The fibroblast growth factor (FGF) gene family to date comprises seven members and has been implicated in a wide range of physiological and biological processes, including angiogenesis, morphogenesis, and tumorigenesis. The FGFs are mitogens for a broad range of cells of various embryological origins and can act as differentiation factors. The FGFs can bind to tyrosine kinase and non-tyrosine kinase transmembrane receptors; the physiological basis for this is still unknown. In order to study more thoroughly the activities of FGF-6, we have constructed a bacterial expression vector by inserting FGF-6 complementary DNA sequences into the T7 RNA polymerase-based pET3a vector. The resulting construct is able to drive the expression of a high amount of FGF-6 protein in Escherichia coli, which can be solubilized and purified through heparin-Sepharose chromatography and high salt elution. The purified FGF-6 protein displays a strong mitogenic activity on BALB/c 3T3 cells and is able to morphologically transform these cells. By contrast, adult bovine aortic endothelial cells, which normally require the presence of FGF-2 for their growth, show only a limited mitogenic response that is highly dependent on heparin concentration.
This article has been cited by other articles:
![]() |
O. A. Ibrahimi, F. Zhang, A. V. Eliseenkova, R. J. Linhardt, and M. Mohammadi Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity Hum. Mol. Genet., January 1, 2004; 13(1): 69 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chellaiah, W. Yuan, M. Chellaiah, and D. M. Ornitz Mapping Ligand Binding Domains in Chimeric Fibroblast Growth Factor Receptor Molecules. MULTIPLE REGIONS DETERMINE LIGAND BINDING SPECIFICITY J. Biol. Chem., December 3, 1999; 274(49): 34785 - 34794. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Ornitz, J. Xu, J. S. Colvin, D. G. McEwen, C. A. MacArthur, F. Coulier, G. Gao, and M. Goldfarb Receptor Specificity of the Fibroblast Growth Factor Family J. Biol. Chem., June 21, 1996; 271(25): 15292 - 15297. [Abstract] [Full Text] [PDF] |
||||
![]() |
O deLapeyriere, V Ollendorff, J Planche, M. Ott, S Pizette, F Coulier, and D Birnbaum Expression of the Fgf6 gene is restricted to developing skeletal muscle in the mouse embryo Development, January 6, 1993; 118(2): 601 - 611. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |